Viavi price target raised to $12 from $11 at Stifel

Stifel raised the firm’s price target on Viavi to $12 from $11 and keeps a Hold rating on the shares. While the company’s Q2 results were above the firms estimates, management characterized FY23 as a “challenging” year, with revenue and EPS declining, the analyst tells investors. The firm views the company’s longer-term prospects positively but will maintain a Hold rating on the shares for now.